Sign up Australia
Proactive Investors - Run By Investors For Investors

Genprex to present at the Singular Research Summer Solstice conference

The biopharmaceutical company is making great strides toward developing its non-small-cell, lung cancer-fighting, gene-therapy drug Oncoprex
A researcher in a lab
Investors can hear Genprex CEO Rodney Varner talk about Oncoprox, which is in Phase 2 clinical trials

Genprex Inc (NASDAQ:GNPX), a clinical-stage gene-therapy company, announced Thursday that CEO Rodney Varner will present at the Singular Research Summer Solstice 2018 in New York City.

Varner will be presenting Thursday at 10.40 am ET at the high-profile conference in the small- and micro-cap space.

The Austin, Texas-based biopharmaceutical company is making great strides toward developing its non-small-cell, lung cancer-fighting, gene-therapy drug Oncoprex.

Varner earlier told Proactive Investors that Oncoprox is in Phase 2 of clinical trials, and next steps are to meet with the FDA about best pathways forward to an approval.

The company recently went public, raising $6.4mln. Varner said the biopharma will use the funds to continue clinical trials and expand and/or accelerate development programs into additional drug combinations.

Investors will be tuning into the conference for more details about progress on Oncoprox.

Investor excitement about the lung cancer-fighting, gene-therapy drug sent Genprex stock more than 1% higher to US$7.39 on Thursday's premarket action.

Contact Uttara Choudhury at [email protected]

Follow her on Twitter@UttaraProactive 

View full GNPX profile View Profile

Genprex, Inc. Timeline

Related Articles

Vial of pills
June 25 2018
Cosmos is a modern company, but the trade routes it relies on are ancient
woman at a microscope
August 02 2018
Currently undergoing phase III clinical trials, AP101 is being developed to treat Epidermolysis Bullosa, a condition which occurs prominently in children and makes skin fragile to even the faintest touch
picture of cannabis plants
March 24 2018
Control of the supply chain offers operational advantages and financial benefits.

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use